Prospective Associations of Plasma Growth Differentiation Factor 15 With Physical Performance and Cognitive Functions in Older Adults

Media type: E-Article
Title: Prospective Associations of Plasma Growth Differentiation Factor 15 With Physical Performance and Cognitive Functions in Older Adults
Contributor: He, Lingxiao; de Souto Barreto, Philipe; Sánchez Sánchez, Juan Luis; Rolland, Yves; Guyonnet, Sophie; Parini, Angelo; Lucas, Alexandre; Vellas, Bruno; Vellas, Bruno; Guyonnet, Sophie; Carrié, Isabelle; Brigitte, Lauréane; Faisant, Catherine; Lala, Françoise; Delrieu, Julien; Villars, Hélène; Emeline Combrouze, Psychologists:; Badufle, Carole; Zueras, Audrey; Cantet, Christelle; Morin, Christophe; Abellan Van Kan, Gabor; Dupuy, Charlotte; Rolland, Yves; [...]
imprint: Oxford University Press (OUP), 2022
Published in: The Journals of Gerontology: Series A
Language: English
DOI: 10.1093/gerona/glac020
ISSN: 1079-5006; 1758-535X
Keywords: Geriatrics and Gerontology ; Aging
Origination:
Footnote:
Description: <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Growth differentiation factor 15 (GDF15) has been associated with several age-related disorders, but its associations with functional abilities in community-dwelling older adults are not well studied.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>The study was a secondary analysis of 1 096 community-dwelling older adults (aged 69–94 years) recruited from the Multidomain Alzheimer’s Preventive Trial. Plasma GDF15 was measured 1 year after participants’ enrollment. Annual data of physical performance (grip strength and Short Physical Performance Battery [SPPB]) and global cognitive functions (Mini-Mental State Examination [MMSE] and a composite cognitive score) were measured for 4 years. Adjusted mixed-effects linear models were performed for cross-sectional and longitudinal association analyses.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>A higher GDF15 was cross-sectionally associated with a weaker grip strength (β = −1.1E−03, 95% CI [−2.0E−03, −1.5E−04]), a lower SPPB score (β = −3.1E−04, 95% CI [−5.4E−04, −9.0E−05]), and worse cognitive functions (β = −2.4E−04, 95% CI [−3.3E−04, −1.6E−04] for composite cognitive score; β = −4.0E−04, 95% CI [−6.4E−04, −1.6E−04] for MMSE). Participants with higher GDF15 demonstrated greater longitudinal declines in SPPB (β = −1.0E−04, 95% CI [−1.7E−04, −2.0E−05]) and composite cognitive score (β = −2.0E−05, 95% CI [−4.0E−05, −3.6E−06]). The optimal initial GDF15 cutoff values for identifying participants with minimal clinically significant decline after 1 year were 2 189 pg/mL for SPPB (AUC: 0.580) and 2 330 pg/mL for composite cognitive score (AUC: 0.587).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Plasma GDF15 is cross-sectionally and longitudinally associated with lower-limb physical performance and global cognitive function in older adults. Circulating GDF15 alone has a limited capacity of discriminating older adults who will develop clinically significant functional declines.</jats:p> </jats:sec> <jats:sec> <jats:title>Clinical Trial Registration</jats:title> <jats:p>NCT00672685</jats:p> </jats:sec>

Search in field:

Recently searched for: